Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets

被引:63
作者
Mallipeddi, Srikrishnan [1 ,2 ]
Janero, David R. [1 ,2 ]
Zvonok, Nikolai [1 ,2 ]
Makriyannis, Alexandros [1 ,2 ,3 ]
机构
[1] Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA
[2] Northeastern Univ, Ctr Drug Discovery, Boston, MA 02115 USA
[3] Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA
关键词
GPCR; Biased agonism; Drug discovery; Effector pathways; AGONIST-DIRECTED TRAFFICKING; ARRESTIN-BIASED AGONISM; MU-OPIOID RECEPTOR; CB1; RECEPTOR; SIGNAL-TRANSDUCTION; LIGAND BIAS; CRYSTAL-STRUCTURE; BETA-ARRESTINS; ACTIVATION; ENDOCANNABINOIDS;
D O I
10.1016/j.bcp.2016.11.014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The phenomenon of functional selectivity, whereby a ligand preferentially directs the information output of a G-protein coupled receptor (GPCR) along (a) particular effector pathway(s) and away from others, has redefined traditional GPCR signaling paradigms to provide a new approach to structure-based drug design. The two principal cannabinoid receptors (CBRs) 1 and 2 belong to the class-A GPCR subfamily and are considered tenable therapeutic targets for several indications. Yet conventional orthosteric ligands (agonists, antagonists/inverse agonists) for these receptors have had very limited clinical utility due to their propensity to incite on-target adverse events. Chemically distinct classes of cannabinergic ligands exhibit signaling bias at CBRs towards individual subsets of signal transduction pathways. In this review, we discuss the known signaling pathways regulated by CBRs and examine the current evidence for functional selectivity at CBRs in response to endogenous and exogenous cannabinergic ligands as biased agonists. We further discuss the receptor and ligand structural features allowing for selective activation of CBR-dependent functional responses. The design and development of biased ligands may offer a pathway to therapeutic success for novel CBR-targeted drugs. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 124 条
[41]   A Lipid Pathway for Ligand Binding Is Necessary for a Cannabinoid G Protein-coupled Receptor [J].
Hurst, Dow P. ;
Grossfield, Alan ;
Lynch, Diane L. ;
Feller, Scott ;
Romo, Tod D. ;
Gawrisch, Klaus ;
Pitman, Michael C. ;
Reggio, Patricia H. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (23) :17954-17964
[42]   Structural Basis of Species-Dependent Differential Affinity of 6-Alkoxy-5-Aryl-3-Pyridinecarboxamide Cannabinoid-1 Receptor Antagonists [J].
Iyer, Malliga R. ;
Cinar, Resat ;
Liu, Jie ;
Godlewski, Grzegorz ;
Szanda, Gergoe ;
Puhl, Henry ;
Ikeda, Stephen R. ;
Deschamps, Jeffrey ;
Lee, Yong-Sok ;
Steinbach, Peter J. ;
Kunos, George .
MOLECULAR PHARMACOLOGY, 2015, 88 (02) :238-244
[43]   Biophysical detection of diversity and bias in GPCR function [J].
Jaeger, Werner C. ;
Armstrong, Stephen P. ;
Hill, Stephen J. ;
Pfleger, Kevin D. G. .
FRONTIERS IN ENDOCRINOLOGY, 2014, 5
[44]   Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target [J].
Janero, David R. ;
Thakur, Ganesh A. .
EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (12) :1223-1237
[45]   Terpenes and Lipids of the Endocannabinoid and Transient-Receptor-Potential-Channel Biosignaling Systems [J].
Janero, David R. ;
Makriyannis, Alexandros .
ACS CHEMICAL NEUROSCIENCE, 2014, 5 (11) :1097-1106
[46]   Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists [J].
Janero, David R. .
EXPERT OPINION ON EMERGING DRUGS, 2012, 17 (01) :17-29
[47]   Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk [J].
Janero, David R. ;
Lindsley, Loren ;
Vemuri, Venkata Kiran ;
Makriyannis, Alexandros .
EXPERT OPINION ON DRUG DISCOVERY, 2011, 6 (10) :995-1025
[48]   Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice [J].
Jin, KL ;
Xie, L ;
Kim, SH ;
Parmentier-Batteur, S ;
Sun, YJ ;
Mao, XO ;
Childs, J ;
Greenberg, DA .
MOLECULAR PHARMACOLOGY, 2004, 66 (02) :204-208
[49]  
Jordà MA, 2002, BLOOD, V99, P2786
[50]  
KAMINSKI NE, 1993, ADV EXP MED BIOL, V335, P115